Long-term (≥2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis

Hepato-Gastroenterology

Volumn 60, Issue 126, 2013, Pages 1445-1450

  Sumida, Yoshio ^a   Naito, Yuji ^a   Tanaka, Saiyu ^b   Sakai, Kyoko ^c   Inada, Yutaka ^a   Taketani, Hiroyoshi ^b   Kanemasa, Kazuyuki ^b   Yasui, Kohichiroh ^b   Itoh, Yoshito ^b   Okanoue, Takeshi ^c   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Nara City Hospital   (Japan)

^c Saiseikai Suita Hospital   (Japan)

Author keywords

Insulin resistance; Liver biopsy; Liver fibrosis; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANTIOXIDANT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; LONG TERM CARE; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; BLOOD; FATTY LIVER; MIDDLE AGED; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIOXIDANTS; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDIES; TIME FACTORS; VITAMIN E;

EID: 84885755013     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11421     Document Type: Article

References (38)

1. Ludwig J, Viggiano TR, McGill DB, Ott BJ: Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-438.
2. Matteoni CA, Younossi ZM, Gramlich T, et al.: Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413-1419.
3. Rafiq N, Bai C, Fang Y, et al.: Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7:234-238.
4. Ono M, Saibara T: Clinical features of nonalcoholic steatohepatitis in Japan: evidence from literature. J Gastroenterol 2006; 41:725-732.
5. Sumida Y, Naito Y, Yoshikawa T: Free Radicals and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. In: Free Radical Biology in Digestive Diseases. Frontiers in Gastrointestinal Research. Naito Y, Suematsu M, Yoshikawa T (Eds.). Basel: Karger; 2011, pp. 144-155.
6. Sumida Y, Nakashima T, Yoh T, et al.: Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003; 38:32-38.
7. Sanyal AJ, Chalasani N, Kowdley KV, et al.; NASH CRN: Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. New Engl J Med 2010; 362:1675-1685.
8. Kleiner DE, Brunt EM, Van Natta M, et al.: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321.
9. Japanese Society for the Study of Obesity: New criteria of obesity (in Japanese). J Jpn Soc Study Obes 2000; 6:18-28.
10. American Diabetes Association: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20:1183-1197.
11. Matthews DR, Hosker JP, Rudenski AS, et al.: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
12. Koch W, Latz W, Eichinger M, et al.: Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 2002; 48:1377-1382.
13. Brunt EM, Janney CG, Di Bisceglie AM, et al.: Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474.
14. Adams LA, Sanderson S, Lindor KD, Angulo P: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42:132-138.
15. Argo CK, Northup PG. Abdullah MS, et al.: Systematic review of risk factors for fibrosis progression in nonalcoholic steatohepatitis. J Hepatol 2009; 51:371-379.
16. Ekstedt M, Franz LE, Mathiesen UL, et al: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865-873.
17. Fassio E, Alvarez E, Dominguez N, et al.: Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40:820-826.
18. Harrison SA, Torgerson S, Hayashi PH: The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98:2042-2047.
19. Hamaguchi E, Takamura T, Sakurai M, et al.: Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010; 33:284-286.
20. Neuschwander-Tetri BA, Sanyal AJ, Chalasani NP, et al: Changes in ALT and vitamin E levels and histological response in patients with NASH treated with vitamin E in the PIVENS trial. Hepatology 2010; Suppl:620A.
21. Sanyal AJ, Mofrad PS, Contos MJ, et al.: A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2:1107-1115.
22. Poli G, Albano E, Biasi F, et al.: Lipid peroxidation stimulated by carbon tetrachloride or iron and hepatocyte death: protective effect of vitamin E. In: Free Radicals in Liver Injury. Poli G, Cheeseman KH, Diazani MU, Slater TF (Eds.) Oxford: IRL Press Ltd; 1985, pp.207-215.
23. Parola M, Muraca R, Dianzani I, et al.: Vitamin E dietary supplementation inhibits transforming growth factor b1 gene expression in the rat liver. FEBS Left 1992; 308:267-270.
24. Parola M, Leonarduzzi G, Biasi F, et al.: Vitamin E dietary supplementation protects against carbon tetrachloride induced chronic liver damage and cirrhosis. Hepatology 1992; 16:1014-1021.
25. Hasegawa T, Yoneda M, Nakamura K, et al.: Plasma transforming growth factor- beta 1 level and efficacy of alpha- tocopherol in patients with non- alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15:1667-1672.
26. Harrison SA, Torgerson S, Hayashi P. et al.: Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98:2485-2490.
27. Langlois MR, Delanghe JR: Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42:1589-1600.
28. Carter K, Worwood M: Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int J Lab Hematol 2007; 29:92-110.
29. Zingg JM, Azzi A, Meydani M: Genetic polymorphisms as determinants for disease-preventive effects of vitamin E. Nutr Rev 2008; 66:406-414.
30. Milman U, Blum S, Shapira C, et al.: Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008; 28:341-347.
31. Tsujinaka K, Nakamura T, Maegawa H, et al.: Diet high in lipid hydroperoxide by vitamin E deficiency induces insulin resistance and insulin secretion in normal rats. Diabetes Res Clin Pract 2005; 67:99-109.
32. Vinayaga MR, Boby Z, Selvaraj N, Sridhar MG: Vitamin E protects the insulin sensitivity and redox balance in rat L6 muscle cells exposed to oxidative stress. Clin Chim Acta 2006; 367: 132-136.
33. Yakaryilmaz F, Guliter S, Savas B, et al.: Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 2007; 37:229-235.
34. Nobili V, Manco M, Devito R, et al.: Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006; 24:1553-1561.
35. Nobili V. Manco M, Devito R, et al.: Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48:119-128.
36. Ratziu V, Charlotte F, Heurtier A et al.: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128:1898-1906.
37. Merriman RB, Ferrell LD, Patti MG, et al.: Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44:874-880.
38. Satapathy SK, Sanyal AJ: Novel treatment modalities for nonalcoholic steatohepatitis. Trends Endocrinol Metab 2010; 21:668-775.